Literature DB >> 3316494

Neuropathological substrates of Alzheimer's disease and Parkinson's disease.

K Jellinger1.   

Abstract

The pathology of Alzheimer's disease (AD) and Parkinson's disease (PD) is characterized by degeneration of certain vulnerable neuronal populations that display several types of cytoskeletal abnormalities (Alzheimer-type lesions and Lewy bodies, respectively). These may serve as diagnostic markers, although they can be found in both types of disorders and, less frequently, in brains of normal aged individuals. AD pathology shows a preponderance for hippocampal, neocortical, and forebrain cholinergic systems; the hallmark of PD is damage to the nigrostriatal dopaminergic system. Both disorders show frequent involvement of subcortical projection systems that can be similar in quality and distribution, with similar multiple neuromediator dysfunction. The results of morphometric studies of some subcortical nuclei in AD and PD are reported and related with neurochemical data. In addition to classical forms of AD and PD, both types of lesions can coexist suggesting an increased risk of PD in patients with AD and vice versa. The basis for an association between the two disorders is unknown. Many AD cases with signs of PD have additional PD pathology, while cortical Alzheimer lesions may be seen in demented PD patients. However, dementia in PD does not imply coexistent cortical AD pathology; prominent subcortical lesions alone, or in combination with cortical AD pathology, may occur. AD and PD may show some differences in the primary locus of degenerative changes in specific cortical and subcortical neuronal systems, but the causative factors, mutual relations, and relative contributions to the clinical syndromes remain to be elucidated.

Entities:  

Mesh:

Year:  1987        PMID: 3316494

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  12 in total

1.  Selective loss of nigral neurons in Alzheimer's disease: a morphometric study.

Authors:  T Uchihara; H Kondo; K Kosaka; H Tsukagoshi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2014-12-12       Impact factor: 4.849

4.  Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease.

Authors:  A S Whitehead; S Bertrandy; F Finnan; A Butler; G D Smith; Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

5.  Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.

Authors:  Peter S Myers; John L O'Donnell; Joshua J Jackson; Christina N Lessov-Schlaggar; Rebecca L Miller; Erin R Foster; Carlos Cruchaga; Bruno A Benitez; Paul T Kotzbauer; Joel S Perlmutter; Meghan C Campbell
Journal:  Neurology       Date:  2022-04-13       Impact factor: 11.800

6.  Ganglioglioma with neurofibrillary tangles (NFTs): neoplastic NFTs share antigenic determinants with NFTs of Alzheimer's disease.

Authors:  D Soffer; F Umansky; J E Goldman
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

7.  The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease.

Authors:  K Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

8.  Does Alzheimer's disease begin in the brainstem?

Authors:  G Simic; G Stanic; M Mladinov; N Jovanov-Milosevic; I Kostovic; P R Hof
Journal:  Neuropathol Appl Neurobiol       Date:  2009-08-04       Impact factor: 8.090

9.  Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.

Authors:  P Vieregge; G Ziemens; M Freudenberg; A Piosinski; A Muysers; B Schulze
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

Review 10.  Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.

Authors:  Raquel N Taddei; Seyda Cankaya; Sandeep Dhaliwal; K Ray Chaudhuri
Journal:  Parkinsons Dis       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.